Bank of Nova Scotia increased its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 146.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 24,089 shares of the company's stock after purchasing an additional 14,307 shares during the quarter. Bank of Nova Scotia's holdings in IDEXX Laboratories were worth $9,959,000 at the end of the most recent quarter.
A number of other large investors have also bought and sold shares of the business. Insight Wealth Strategies LLC raised its holdings in IDEXX Laboratories by 230.5% in the 4th quarter. Insight Wealth Strategies LLC now owns 10,096 shares of the company's stock valued at $4,174,000 after acquiring an additional 7,041 shares in the last quarter. Y Intercept Hong Kong Ltd bought a new stake in shares of IDEXX Laboratories during the third quarter valued at about $1,263,000. Sax Wealth Advisors LLC lifted its holdings in shares of IDEXX Laboratories by 76.3% in the 4th quarter. Sax Wealth Advisors LLC now owns 1,426 shares of the company's stock worth $590,000 after acquiring an additional 617 shares during the last quarter. Hantz Financial Services Inc. increased its stake in shares of IDEXX Laboratories by 11.5% in the 4th quarter. Hantz Financial Services Inc. now owns 7,738 shares of the company's stock worth $3,199,000 after acquiring an additional 800 shares in the last quarter. Finally, Paragon Capital Management Inc. lifted its position in IDEXX Laboratories by 25.7% in the 4th quarter. Paragon Capital Management Inc. now owns 3,820 shares of the company's stock valued at $1,579,000 after acquiring an additional 782 shares in the last quarter. 87.84% of the stock is owned by institutional investors.
IDEXX Laboratories Stock Performance
Shares of IDXX stock traded up $2.36 during trading hours on Wednesday, reaching $406.38. The company had a trading volume of 211,349 shares, compared to its average volume of 796,221. The business has a fifty day moving average price of $425.62 and a 200-day moving average price of $432.65. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $548.88. The firm has a market cap of $32.93 billion, a PE ratio of 38.09, a price-to-earnings-growth ratio of 3.41 and a beta of 1.50.
Insider Activity at IDEXX Laboratories
In related news, Director M Anne Szostak sold 3,000 shares of the business's stock in a transaction on Friday, February 7th. The shares were sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the completion of the transaction, the director now owns 3,061 shares in the company, valued at approximately $1,426,242.34. The trade was a 49.50 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP George Fennell sold 9,986 shares of the company's stock in a transaction on Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the transaction, the executive vice president now directly owns 8,176 shares in the company, valued at approximately $3,781,645.28. This trade represents a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.98% of the stock is currently owned by insiders.
Wall Street Analysts Forecast Growth
A number of research analysts have weighed in on IDXX shares. Morgan Stanley cut their price objective on shares of IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating on the stock in a research report on Wednesday, January 29th. Barclays boosted their target price on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 4th. StockNews.com cut IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Saturday. Stifel Nicolaus reduced their price objective on IDEXX Laboratories from $450.00 to $420.00 and set a "hold" rating on the stock in a research report on Monday. Finally, Piper Sandler raised their price objective on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a report on Monday, February 10th. Four analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $523.75.
Read Our Latest Stock Report on IDXX
About IDEXX Laboratories
(
Free Report)
IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
Further Reading
Before you consider IDEXX Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEXX Laboratories wasn't on the list.
While IDEXX Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
